Evidence map›Paper›PMID 33826610›Full record

SynthesisPloS one2021

Use of corticoids and non-steroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review and network meta-analysis.

Mariana Del Grossi Paglia, Marcus Tolentino Silva, Luciane Cruz Lopes, Silvio Barberato-Filho, Lauren Giustti Mazzei, Flavia Casale Abe, Cristiane de Cássia Bergamaschi

Open access · goldAbstract readNetwork Meta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 3 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 64 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. UK Medical Cannabis Registry: An Updated Analysis of Inflammatory Arthritis.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2026
    Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mariana Del Grossi PagliaGraduate Program in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, State of São Paulo, Brazil.ORCID 0000-0003-4268-4298
Marcus Tolentino SilvaGraduate Program in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, State of São Paulo, Brazil.ORCID 0000-0002-7186-9075
Luciane Cruz LopesGraduate Program in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, State of São Paulo, Brazil.
Silvio Barberato-FilhoGraduate Program in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, State of São Paulo, Brazil.
Lauren Giustti MazzeiGraduate Program in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, State of São Paulo, Brazil.ORCID 0000-0001-8611-5594
Flavia Casale AbeGraduate Program in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, State of São Paulo, Brazil.ORCID 0000-0002-0889-4673
Cristiane de Cássia BergamaschiGraduate Program in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, State of São Paulo, Brazil.
Universidade de Sorocaba · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Evidence on the use of non-steroidal anti-inflammatory drugs (NSAIDs) and corticoids for rheumatoid arthritis (RA) is inconclusive and is not up to date. This systematic review assessed the effectiveness and safety of these anti-inflammatories (AI) in the treatment of RA. COCHRANE (CENTRAL), MEDLINE, EMBASE, CINAHL, Web of Science and Virtual Health Library were searched to identify randomized controlled trials (RCT) with adults which used AI (dose represented in mg/day) compared with placebo or active controls and was carried out up to December of 2019. Reviewers, in pairs and independently, selected studies, performed the data extraction and assessed the risk of bias. The quality of the evidence was assessed by GRADE. Network meta-analyses were performed using the Stata v.14.2. Twenty-six articles were selected (NSAIDs = 21 and corticoids = 5). Naproxen 1,000 improved physical function, reduced pain and the number of painful joints compared to placebo. Etoricoxib 90 reduced the number of painful joints compared to placebo. Naproxen 750 reduced the number of swollen joints, except for etoricoxib 90. Naproxen 1,000, etoricoxib 90 and diclofenac 150 were better than placebo regarding patient assessment. Assessment physician showed that NSAIDs were better than placebo. Meta-analyses were not performed for prednisolone and prednisone. Naproxen 1,000 was the most effective drug and celecoxib 200 showed fewer adverse events. However, the low quality of the evidence observed for the outcomes with NSAIDs, the absence of meta-analyses to assess the outcomes with corticoids, as well as the risk of bias observed, indicate that future RCT can confirm such findings.

Indexed as

Adrenal Cortex HormonesAnti-Inflammatory Agents, Non-SteroidalArthritis, RheumatoidFemaleHumansMaleMiddle AgedAdrenal Cortex HormonesAnti-Inflammatory Agents, Non-Steroidal

Identifiers

PMID33826610
PMCPMC8026036
OpenAlexW3143747006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.